Parkinson's disease (PD) and Huntington’s disease (HD) are chronic neurodegenerative
disease characterized clinically by disorder of movements. The underlying mechanisms
of neurodegeneration in PD and HD are still unknown, and there are no disease-modifying
treatments to slow the neurodegenerative processes. There is an urgent need to identify
biomarkers able to monitor disease progression and assess the development and efficacy
of novel disease-modifying drugs. Over the past years, neuroimaging techniques such
as magnetic resonance imaging (MRI) and positron emission tomography (PET) have provided
important advances in our understanding of PD and HD. PET can detect molecular changes
in the brain, and it is therefore a more specific technique to assess neurotransmitter
and receptor abnormalities in PD and HD brains in vivo.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
